Novo's Long-Acting Insulin, Tresiba, Safe and Effective

Novo Nordisk's new long-acting insulin, Tresiba (insulin degludec), has been shown to be effective and safe for long-term use in children and young adults with type 1 diabetes, according to new data from a late-stage trial presented on Tuesday.

Long-acting Tresiba is an important product for future growth at the company, which is the world's top insulin maker.

However, US regulators have refused to approve Tresiba due to potential heart risks, dealing a blow to the company. Tresiba was approved in the European Union last year.

Results of the first trial to look at the long-term safety of Tresiba in children aged 1 to 18 years over a 52-week period showed it improved blood sugar control without increasing the risk of hypoglycaemia.

Read the complete report: http://bit.ly/1uUeUWl

Source: Medscape